Verastem Oncology is committed to advancing cancer treatment for patients with RAS/MAPK pathway mutations, a significant driver of tumor growth and resistance. Their innovative therapies, like the FDA-approved AVMAPKI FAKZYNJA CO-PACK, specifically target recurrent KRAS-mutated low-grade serous ovarian cancer, addressing a critical unmet need in oncology. With ongoing clinical trials and an expanding pipeline, Verastem is poised to make a substantial impact in the evolving landscape of cancer care.
No jobs found. Subscribe below to get notified when we find something for you.
Searching
Companies
Want job alerts that match your preferences?
Set up job preferences →